Prenosis, Inc., a Chicago, IL-based AI company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH).
The grants will study the use of Prenosis’s Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients’ health states rapidly evolve in acute care environments.
The grants are titled “Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis”, and “Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map”.
What You Should Know: – Humana Inc., a health and well-being company, and kidney care management company Interwell Health are expanding their value-based care agreement
A team of investigators from Massachusetts General Hospital (MGH), Brigham and Women’s Hospital (BWH), and the Broad Institute of MIT and Harvard have developed a
Prenosis Awarded Grants to Enable Precision Medicine for Sepsis
by Jasmine Pennic Leave a Comment
What You Should Know:
Humana, Interwell Health Expand Value-Based Kidney Care Agreement to Florida
What You Should Know: – Humana Inc., a health and well-being company, and kidney care management company Interwell Health are expanding their value-based care agreement
Novartis used a PRV to speed Kisqali’s latest indication, FDA says
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Non-invasive genetic test for fetal DNA sequencing developed
A team of investigators from Massachusetts General Hospital (MGH), Brigham and Women’s Hospital (BWH), and the Broad Institute of MIT and Harvard have developed a